Nifty
:
18539.75
Sensex
:
62422.04
27.00 (0.15%)
128.40 (0.21%)
Nifty
Sensex
:
:
18539.75
62422.04
27.00 (0.15%)
128.40 (0.21%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
65/99

BSE: 524715 | NSE: SUNPHARMA

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 247,923.28
  • 60.40
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 243,820.62
  • 0.97%
  • 4.67

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 2.31%
  • 5.91%
  • FII
  • DII
  • Others
  • 15.99%
  • 18.58%
  • 2.73%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.09
  • 7.91
  • 5.59

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.35
  • 12.29
  • 7.22

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.96
  • 9.17
  • -4.53

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 39.06
  • 41.30
  • 53.59

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.27
  • 3.24
  • 3.42

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.93
  • 16.95
  • 17.27

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Net Sales
10,952.28
9,625.93
13.78%
10,761.76
9,718.74
10.73%
9,446.76
8,522.98
10.84%
9,863.06
8,836.78
11.61%
Expenses
7,995.73
6,995.99
14.29%
8,023.04
6,977.54
14.98%
7,267.41
6,474.54
12.25%
7,256.73
6,502.27
11.60%
EBITDA
2,956.55
2,629.94
12.42%
2,738.72
2,741.20
-0.09%
2,179.35
2,048.44
6.39%
2,606.33
2,334.51
11.64%
EBIDTM
26.99%
27.32%
25.45%
28.21%
23.07%
24.03%
26.43%
26.42%
Other Income
85.22
222.89
-61.77%
147.81
232.40
-36.40%
274.61
111.00
147.40%
432.51
386.58
11.88%
Interest
19.39
35.95
-46.06%
13.69
35.09
-60.99%
37.34
30.10
24.05%
18.97
26.10
-27.32%
Depreciation
609.95
530.37
15.00%
588.00
503.22
16.85%
556.47
553.49
0.54%
553.68
531.94
4.09%
PBT
2,412.43
2,286.51
5.51%
2,284.84
1,804.22
26.64%
-2,075.60
903.04
-
2,466.19
2,163.05
14.01%
Tax
152.26
197.78
-23.02%
188.99
395.57
-52.22%
146.76
55.04
166.64%
335.39
244.94
36.93%
PAT
2,260.17
2,088.73
8.21%
2,095.85
1,408.65
48.78%
-2,222.36
848.00
-
2,130.80
1,918.11
11.09%
PATM
20.64%
21.70%
19.48%
14.49%
-23.53%
9.95%
21.60%
21.71%
EPS
9.43
8.53
10.55%
8.59
6.02
42.69%
-9.49
3.73
-
8.58
7.72
11.14%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
41,023.86
38,654.49
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
11,299.86
Net Sales Growth
11.77%
15.39%
2.01%
12.98%
10.03%
-15.63%
11.38%
2.62%
70.34%
42.31%
 
Cost Of Goods Sold
10,788.52
10,351.54
8,690.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
2,777.68
2,076.36
Gross Profit
30,235.34
28,302.95
24,808.06
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
13,302.68
9,223.50
GP Margin
73.70%
73.22%
74.06%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
82.73%
81.62%
Total Expenditure
30,542.91
28,772.68
25,030.42
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
6,437.76
Power & Fuel Cost
-
702.78
627.09
621.89
613.60
559.97
525.09
545.44
560.77
232.41
187.10
% Of Sales
-
1.82%
1.87%
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
1.45%
1.66%
Employee Cost
-
7,300.83
6,862.23
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
1,534.53
% Of Sales
-
18.89%
20.49%
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
12.90%
13.58%
Manufacturing Exp.
-
1,880.71
1,723.78
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
815.49
618.43
% Of Sales
-
4.87%
5.15%
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
5.07%
5.47%
General & Admin Exp.
-
3,270.55
3,179.45
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
978.48
793.38
% Of Sales
-
8.46%
9.49%
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
6.08%
7.02%
Selling & Distn. Exp.
-
4,075.02
3,103.96
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
763.01
% Of Sales
-
10.54%
9.27%
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
8.67%
6.75%
Miscellaneous Exp.
-
1,191.25
843.83
963.29
1,107.57
1,047.60
1,106.04
1,824.56
1,254.03
847.67
763.01
% Of Sales
-
3.08%
2.52%
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
5.27%
4.11%
EBITDA
10,480.95
9,881.81
8,467.72
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
4,862.10
EBITDA Margin
25.55%
25.56%
25.28%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
43.28%
43.03%
Other Income
940.15
1,437.42
859.17
651.59
1,059.44
912.08
1,030.20
658.25
637.89
592.59
422.23
Interest
89.39
127.35
141.43
302.73
555.25
517.57
399.80
523.24
578.99
44.19
43.16
Depreciation
2,308.10
2,143.74
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
409.23
336.17
PBT
5,087.86
9,048.14
7,105.51
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
4,905.00
Tax
823.40
1,075.50
514.69
822.80
600.88
911.04
1,211.57
913.77
914.69
702.17
845.55
Tax Rate
16.18%
24.00%
18.39%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
15.33%
19.57%
PAT
4,264.46
3,289.27
2,916.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
3,141.47
2,989.59
PAT before Minority Interest
4,120.92
3,405.82
2,284.68
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
3,879.00
3,475.87
Minority Interest
-143.54
-116.55
631.47
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
-737.53
-486.28
PAT Margin
10.40%
8.51%
8.71%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
19.54%
26.46%
PAT Growth
-31.92%
12.79%
-22.85%
41.73%
25.73%
-69.50%
53.04%
-0.17%
44.90%
5.08%
 
EPS
17.77
13.71
12.15
15.75
11.12
8.84
28.99
18.94
18.97
13.09
12.46

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
48,011.22
46,462.78
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
18,524.95
14,989.73
Share Capital
239.93
239.93
239.93
239.93
239.93
239.93
240.66
207.12
207.12
103.56
Total Reserves
47,771.29
46,222.85
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
18,317.83
14,886.17
Non-Current Liabilities
-1,363.51
-1,515.17
246.05
76.72
46.43
599.87
2,169.59
2,335.46
1,748.41
199.02
Secured Loans
0.00
7.83
6.18
109.47
217.69
185.59
7.73
40.69
43.76
41.90
Unsecured Loans
229.92
646.88
2,022.74
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
4.91
73.36
Long Term Provisions
369.07
327.12
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
2,601.62
787.06
Current Liabilities
17,200.55
16,145.63
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
2,841.25
Trade Payables
4,479.34
3,973.66
3,583.64
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
1,057.99
Other Current Liabilities
2,926.73
4,965.34
2,535.02
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
260.41
218.65
Short Term Borrowings
468.52
2,444.90
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
82.95
Short Term Provisions
9,325.96
4,761.73
4,038.39
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
1,481.66
Total Liabilities
66,903.15
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
Net Block
22,459.74
21,552.98
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
5,647.47
Gross Block
38,501.94
35,578.99
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
10,485.12
8,709.22
Accumulated Depreciation
16,042.20
14,026.01
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
7,724.42
3,667.84
3,061.75
Non Current Assets
31,888.17
33,668.21
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
8,161.89
Capital Work in Progress
1,286.80
1,566.83
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
841.54
562.61
Non Current Investment
5,214.65
6,482.39
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
787.56
1,106.35
Long Term Loans & Adv.
2,880.86
4,061.34
4,104.48
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
1,016.98
802.56
Other Non Current Assets
46.12
4.67
5.53
21.96
50.21
682.18
953.34
103.94
34.20
42.90
Current Assets
35,014.98
30,442.08
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
11,503.03
Current Investments
7,633.94
3,130.06
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
1,998.46
1,305.22
Inventories
8,996.81
8,997.02
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
2,577.76
Sundry Debtors
10,592.89
9,061.40
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
2,412.23
Cash & Bank
5,033.35
6,445.51
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
4,058.71
Other Current Assets
2,757.99
1,319.11
1,541.48
1,266.30
2,919.93
3,546.51
2,847.64
5,026.16
3,774.42
1,149.11
Short Term Loans & Adv.
1,692.55
1,488.98
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
952.93
Net Current Assets
17,814.43
14,296.45
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
8,661.78
Total Assets
66,903.15
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
8,984.54
6,170.37
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
3,356.58
PBT
4,481.32
2,799.37
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
4,314.89
Adjustment
1,974.95
1,809.85
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
-40.15
160.00
Changes in Working Capital
1,559.05
2,564.09
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
207.10
-44.83
Cash after chg. in Working capital
8,015.32
7,173.31
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
4,430.06
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
969.22
-1,002.94
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
-1,073.48
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5,724.74
536.22
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
-2,635.05
Net Fixed Assets
-1,120.95
-8,061.35
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
-380.81
-341.28
Net Investments
-11.67
1,824.52
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
120.24
Others
-4,592.12
6,773.05
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
712.24
-2,414.01
Cash from Financing Activity
-5,193.46
-5,980.48
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
-664.99
Net Cash Inflow / Outflow
-1,933.66
726.11
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
2,099.01
56.54
Opening Cash & Equivalents
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
1,752.67
Closing Cash & Equivalent
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70
2,069.11

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
200.11
193.65
188.66
172.59
159.69
152.70
137.03
123.49
89.44
72.37
ROA
5.20%
3.54%
6.58%
5.17%
4.24%
0.00%
11.39%
14.60%
16.21%
19.61%
ROE
7.21%
4.98%
9.66%
8.05%
6.85%
0.00%
19.32%
24.89%
23.15%
25.53%
ROCE
9.32%
5.68%
10.07%
8.68%
8.40%
0.00%
18.64%
25.06%
25.46%
31.39%
Fixed Asset Turnover
1.81
1.74
1.78
1.92
1.99
1.29
1.34
1.79
1.70
1.51
Receivable days
53.38
54.88
56.22
54.10
53.53
83.25
76.12
48.20
51.72
71.46
Inventory Days
48.87
50.10
48.40
47.84
48.88
78.98
77.46
57.99
63.92
74.22
Payable days
149.03
158.71
152.86
77.81
90.19
85.47
75.24
52.05
56.33
65.15
Cash Conversion Cycle
-46.77
-53.73
-48.24
24.13
12.23
76.75
78.34
54.14
59.31
80.53
Total Debt/Equity
0.02
0.08
0.18
0.25
0.27
0.27
0.26
0.35
0.14
0.02
Interest Cover
36.19
20.79
17.55
7.86
7.72
23.63
13.56
12.06
104.67
101.13

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Sun Pharma, SPARC get nod from USFDA for SEZABY
    18th Nov 2022, 14:09 PM

    SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection

    Read More
  • Sun Pharma, SPARC enter into license agreement for commercialization of phenobarbital for injection in US
    9th Nov 2022, 13:01 PM

    Currently, there are no phenobarbital injection products approved by the US FDA for the treatment of seizures in newborns

    Read More
  • Sun Pharma's Mohali plant receives OAI status from USFDA
    9th Nov 2022, 09:59 AM

    The plant was inspected in August and had received a form 483 with six observations earlier

    Read More
  • Sun Pharmaceutical Industries reports 8% rise in Q2 consolidated net profit
    1st Nov 2022, 15:35 PM

    Total consolidated income of the company increased by 12.07% to 11037.50 crore for Q2FY23

    Read More
  • Sun Pharma Inds. - Quarterly Results
    1st Nov 2022, 13:36 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.